Episode 81: Accelerating Discovery to Market

Episode 81: Accelerating Discovery to Market

From TGen Talks by TGen

April 30, 2025 · 20 min

About this episode

Dr. Stephanie Pond discusses the role of TGen's programs in accelerating the translation of biomedical research into treatments.

This month on TGen Talks, we get an insider’s perspective on how today’s biomedical research translates into tomorrow's treatments. We sit down with Stephanie Pond, Ph.D., Vice President of Emerging Opportunities at TGen. We’ll Learn about the crucial role of TGen’s START and EDP programs – the Scientific Technology Assessment Research Team and Enterprise Directed Programs – in accelerating this process. Dr. Pond explains how her team works to identify gaps in current research tools, partner with biotechnology companies to develop new technologies, and help commercialize TGen’s research discoveries. She highlights how advances in multiomics, single-cell sequencing, and spatial technologies are transforming biomedical research and enabling new diagnostic tests and treatments. Dr. Pond also discusses TGen's Enterprise Directed Programs, which focuses on taking research discoveries and developing scalable clinical tests and products. Join us to hear Dr. Pond’s passion for technology and science and her dedication to bringing personalized medicine to life, faster.

People in this episode

Guest: Stephanie Pond Ph D

Topics covered

  • biomedical research
  • personalized medicine
  • multiomics
  • single-cell sequencing
  • spatial technologies

Keywords

  • START
  • EDP
  • Scientific Technology Assessment Research Team
  • Enterprise Directed Programs
  • commercialization

Mentioned in this episode

Products: multiomics, single-cell sequencing, spatial technologies

More episodes of TGen Talks

Explore listener stats, chart rankings, contacts and more on the TGen Talks podcast page.